

**Chammas & Marcheteau advises Turenne Santé on  
Kimialys' €3.6 million fundraising (Nanotechnologies/Medtech)**

---

**Chammas & Marcheteau** advised Turenne Santé, through its fund Relyens Innovation Santé, lead investor in Kimialys' €3.6 million Series A fundraising, carried out alongside Octalfa, Evolem and historical investors Odiem Capital, Badge and Angels Santé.

Founded in 2020, Kimialys develops and commercializes a technological platform based on an innovative chemical approach for the treatment of surfaces used in the field of diagnostics and in vitro analysis (nanoparticles, biochips or electrodes).

This financing will enable Kimialys to complete the industrialization of its processes, in particular by scaling up its production capacity, to develop an initial catalog of ready-to-use kits, and to intensify its commercial efforts, primarily internationally.

The **Chammas & Marcheteau** team consisted of **Stéphanie Bréjaud** (partner) and **Jeanne Cormerais** (associate) on corporate aspects, and **Coline Bied-Charreton** (partner), **Floriane Maginot** and **Ensar Tasci** (associates) on employment law aspects.

---

**About Chammas & Marcheteau**

Chammas & Marcheteau is a Paris-based independent law firm that advises companies, investment funds and entrepreneurs on their transactions and development strategies in France and abroad. With more than 60 specialists in business law, including 16 partners, the Firm offers its clients expertise in Private Equity, Mergers & Acquisitions, Funds and Financial Services, Corporate, Restructuring and Turnaround, Tax, Intellectual Property and Information Technology, Employment Law, Real Estate and Business Litigation.